After the greater initial decrease ( 0-18 weeks ) in glycated haemoglobin ( HbA1c ) with glipizide , the 18-104-week HbA1c coefficient of failure ( CoF ) was lower with dapagliflozin ( 0.13 % / year ) than with glipizide ( 0.59 % / year ) , resulting in significant dapagliflozin versus glipizide differences of -0.46 % / year ( 95 % CI -0.60 , -0.33 ; p = 0.0001 ) for CoF and -0.18 % ( -2.0 mmol/mol ) [ 95 % CI -0.33 ( -3.6 ) , -0.03 ( -0.3 ) ; p = 0.021 ] for 104-week HbA1c .